Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Total 13F shares
-
65,481,898
-
Share change
-
-2,364,522
-
Total reported value
-
$6,240,143,536
-
Put/Call ratio
-
119%
-
Price per share
-
$95.35
-
Number of holders
-
235
-
Value change
-
-$246,149,121
-
Number of buys
-
119
-
Number of sells
-
135
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q2 2021
As of 30 Jun 2021,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
235 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
65,481,898 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, Capital International Investors, Capital Research Global Investors, FEDERATED HERMES, INC., BlackRock Inc., Capital World Investors, Clearbridge Investments, LLC, ALKEON CAPITAL MANAGEMENT LLC, and CITADEL ADVISORS LLC.
This page lists
235
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.